What medicine is Vorinostat?

Epigenetic regulation of gene transcription by small molecule inhibitors of histone deacetylase is a new approach to cancer treatment. Vorinostat is the first HDAC inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) and is formulated into capsules. . In Phase I development, vorinostat is active against solid tumors and hematological malignancies as intravenous and oral formulations.

Vorinostat is a drug containing the active substance Vorinostat, which blocks the activity of a protein called histone deacetylase, which is involved in turning genes "on" and "off" within cells. In two phase II trials, vorinostat 400 mg/day was safe and effective, with an overall response rate of 24-30% in patients with refractory advanced cutaneous T-cell lymphoma, including large cell transformation and Sézary syndrome. Common side effects of vorinostat were similar across studies and included gastrointestinal symptoms, systemic symptoms, hematological abnormalities, and dysgeusia, with the most common serious adverse drug events being pulmonary embolism and anemia.

The original drug of vorinostat is not currently on the market in China, and therefore cannot be included in the national medical insurance coverage. Overseas, there is an American version of the original drug, specifications100mg*120 pills per box, which may cost around 100,000 yuan (the price may fluctuate due to exchange rate effects). It is very expensive, and there is currently no generic version of vorinostat produced and launched. For more drug information and specific prices, please consult a medical consultant.